JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Mechanism of Action
SGLT2 inhibitors have multiple effects on metabolism and fluid balance in the Cardio-Renal-Metabolic (CRM) interconnected system1
Sodium-glucose cotransporter 2 (SGLT2) is highly expressed in the kidney. By blocking reuptake of glucose and sodium in the kidneys SGLT2 inhibitors increase the excretion of both in the urine.
Indications
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® (empagliflozin) is a reversible, highly potent and selective competitive inhibitor of sodium-glucose cotransporter 2 (SGLT2).1
In addition to glucose lowering, JARDIANCE® (empagliflozin) demonstrated secondary benefits of reduction in weight and blood pressure although it is not licensed for this.
SGLT2 inhibitors: mode of action
Learn more
Safety profile
Clinical studies
JARDIANCE® efficacy data across the LVEF spectrum
Abbreviations
ARR: absolute risk reduction; CI: confidence interval; CRM: cardio-renal-metabolic; CV: cardiovascular; HbA1c: glycated haemoglobin; CVD: cardiovascular disease; HR: heart rate; HHF = hospitalisation for heart failure; NNT: number needed to treat; LV: left ventricular; LVEF = left ventricular ejection fraction; RRR: relative risk reduction; SGLT2: sodium-glucose co-transporter-2; SGLT2is: sodium-glucose co-transporter-2 inhibitors; SoC: standard of care.
References
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
- Heise T et al. Clin Ther 2016;38:2265.
- Vallon V & Thomson SC. Diabetologia 2017;60:215.
- Verma S et al. Circulation 2019;140:1693.
- Verma S et al. JAMA Cardiol 2017;2:939.
- Abdelgadir E et al. J Clin Med Res 2018;10:615.
- Rajasekeran H et al. Kidney Int 2016;89:524.
- Baartscheer A et al. Diabetologia 2017;60:568.
- Garg V et al. Prog Cardiovasc Dis 2019;62:349.
- Zinman B et al. N Engl J Med 2015;373:2117.
- Wanner C et al. N Engl J Med 2016;375:323.
- Chilton R et al. Diabetes Obes Metab. 2015;17:1180–1193.
PC-GB-108858 V2
February 2024